How common is Ehlers-Danlos Syndrome and joint hypermobility?

Hypermobile EDS combined with hypermobility spectrum disorder (HSD) is now estimated at roughly 19 per 10,000 people, or about 1 in 526 — and the literature itself states this is likely an undercount, since hypermobile EDS has no genetic test and is diagnosed clinically. Rarer EDS subtypes are far less common: classical EDS affects about 1 in 20,000-40,000, vascular EDS about 1 in 100,000-200,000. Separately, generalised joint hypermobility without a formal EDS/HSD diagnosis is far more widespread in the general population: 10-20% of adults, up to 38.8% in some studied populations of children and young adults.

Why does Ehlers-Danlos Syndrome cause fatigue that sleep doesn't fix?

Joint instability forcing muscles to overcompensate is part of the picture, but the research points to something bigger: an estimated 80% of people with hypermobile EDS also have some degree of POTS (postural orthostatic tachycardia syndrome), where the same lax connective tissue that destabilizes joints also destabilizes blood vessel walls, making it harder for the autonomic nervous system to regulate blood flow, especially on standing. That is a circulatory and neurological problem, not a muscular one — which is why rest alone often does not resolve it.

Can circulation-boosting supplements make POTS symptoms worse?

Potentially yes. Standard POTS management explicitly avoids vasodilators, since widening already-lax blood vessels can worsen orthostatic symptoms rather than improve them; treatment instead focuses on blood volume expansion and vasoconstriction support. This means common vasodilation-based circulation advice may be the wrong direction for someone whose fatigue is driven by POTS, even though the same advice is genuinely useful for other cardiovascular contexts.

What botanicals support connective tissue integrity in EDS?

Gotu Kola (Centella asiatica) has the strongest clinical evidence, with a meta-analysis of 8 randomized controlled trials showing improvement in chronic venous insufficiency via stimulated collagen and glycosaminoglycan synthesis. Cissus quadrangularis, used traditionally in Ayurveda and West African bone-setting practice, has human trial evidence for fracture healing and joint/tendon support, though a summarizing meta-analysis grades that evidence as low quality. Vitamin C is an essential enzymatic cofactor for collagen cross-linking, copper is required by the enzyme (lysyl oxidase) that cross-links collagen and elastin, and manganese activates the enzyme (prolidase) that recycles proline for collagen synthesis.

Did ancient physicians describe joint hypermobility?

Yes. Hippocrates, in 'On the Articulations' (Part 8), explicitly describes a constitutional difference in how easily joints dislocate: people with a moist, flabby constitution can dislocate joints without pain, while inflammation normally 'binds' a joint and people who mount a weaker inflammatory response after a dislocation are more prone to recurrence. A related passage in 'Airs, Waters, Places' describes Scythian riders whose joints were so lax from constitutional 'softness and moistness' that they were cauterized to deliberately stiffen the joints for archery and combat.

Sovereign Biology Connective Tissue · POTS · Terrain By Jasper Vermeer · 12 September 2026

EDS Fatigue Isn't Muscular.
It's Circulatory.

If you have Ehlers-Danlos Syndrome, you've probably explained your fatigue the same way almost everyone with it does: unstable joints force your muscles to work overtime just holding you together. That's real. It's also, usually, not the biggest piece of the story — and the piece that's missing explains why sleep never seems to touch it.

One connective-tissue defect, two downstream systems, one wrong direction of "help." → The protocol.

The Number Nobody Agrees On

Hypermobile EDS (hEDS) has no genetic test. It's diagnosed entirely on clinical criteria, which is exactly why the prevalence numbers keep moving — and why the honest answer is a range, not a headline figure.

1 in 526 current estimate for hEDS + hypermobility spectrum disorder (HSD) combined

10–20% of adults with generalised joint hypermobility, without a formal EDS/HSD diagnosis

1 in 100,000+ for vascular EDS — rare, and the subtype with real vessel-rupture risk

The Ehlers-Danlos Society itself states hEDS is "likely more common than previously thought, but how much more common is not yet clear." (Ehlers-Danlos Society, 2026) That 1-in-526 figure and the 10-20% general-hypermobility figure are not the same population — one is a clinical diagnosis, the other is a trait that many people carry with no complaints at all. Confusing the two makes both numbers meaningless.

What's Usually Missing From the Muscle Explanation

The joint-instability-forces-muscle-overcompensation mechanism is real and well documented. But a 2017 review in the American Journal of Medical Genetics names something else as the more central, unifying driver of hEDS fatigue: dysautonomia — the autonomic nervous system's regulation of the body breaking down, not the muscles themselves. At least 20% of hEDS patients meet formal criteria for ME/CFS. (Hakim et al., AJMG Part C, 2017; PMID 28186393)

The single biggest piece of that dysautonomia picture has a name most people with EDS have never been told to ask about.

The 80% Nobody Mentions

The same connective tissue that holds your joints together also gives your blood vessel walls their tone. When that tissue is lax, vessel walls are lax too — and the autonomic nervous system has to work harder to keep blood flowing correctly when you stand up. That combination has a name: POTS, postural orthostatic tachycardia syndrome.

~80% of hEDS patients show some degree of POTS/dysautonomia, per commonly cited estimates

17.9–50% of POTS patients, conversely, meet hEDS criteria — the relationship runs both directions

~90% of hEDS patients report gastrointestinal dysfunction, often driven by the same autonomic root

(ScienceDirect systematic review, S1566070219303029; Mathias et al., dysautonomia review, 2021; Harris et al., Practical Gastroenterology, 2024)

This reframes the fatigue question entirely. It isn't that muscles get tired from overwork and rest should fix it. It's that the system regulating blood flow to the brain and muscles is structurally compromised at the vessel-wall level — a circulatory and neurological problem wearing a muscular disguise. Mast Cell Activation Syndrome (MCAS) shows up significantly more often in hEDS too, adding a third, inflammatory layer on top of the first two. (PMC12063504)

Why "Boost Your Circulation" Can Backfire

This is the part worth sitting with if you've ever looked into energy or circulation protocols for fatigue: a lot of standard advice — cacao, ginkgo, anything that widens blood vessels — is built to help circulation by relaxing vessel walls further. If POTS is part of your picture, that's the wrong direction.

Standard POTS management explicitly avoids vasodilators, precisely because widening vessels that are already too lax worsens the blood-pooling and tachycardia POTS produces. Treatment instead centers on expanding blood volume (salt, fluids, fludrocortisone) and supporting vasoconstriction (compression garments, midodrine). (PMC10259876, systematic review of POTS pharmacotherapy)

None of this means circulation-support botanicals are wrong for everyone. It means the mechanism has to match the person — and for someone with EDS-associated POTS, a vasodilation-first approach is a plausible way to make orthostatic symptoms worse while intending to help.

2,400 Years Ago, Someone Already Described This

The idea that some people's joints are constitutionally looser than others isn't new. It's in the Hippocratic Corpus.

"One constitution differs much from another as to the facility with which dislocations in them may be reduced... the articulations are more subject to mucosities in those who are lean than in those who are fleshy." Elsewhere in the same section: inflammation normally "binds" a joint after injury — and a weaker inflammatory response leaves a joint prone to dislocating again. Hippocrates, On the Articulations, Part 8, trans. Francis Adams (1849)

A related passage, in a different work from the same Hippocratic Corpus, describes Scythian riders whose joints were so constitutionally lax — from what Hippocrates calls the "softness and moistness" of their build — that archery and combat were difficult, and describes them being deliberately cauterized on the shoulders, arms, wrists and hips to stiffen the joints. (Hippocrates, Airs, Waters, Places)

This is a genuine, 2,400-year-old description of what would now be called constitutional joint hypermobility — body type and tissue quality as an inherent trait, independent of any single injury. It's worth being precise about scope: most of "On the Articulations" is technical dislocation-reduction surgery, not laxity theory. Part 8 is a small, real, and remarkably specific exception inside a much larger surgical manual.

The Terrain Underneath the Genetics

EDS is genetic — a mutation in a collagen-related gene. Nothing below changes that. What it can plausibly influence is how much the underlying vulnerability is compounded on top of the genetic baseline, through the enzymes and raw materials the body still needs to process whatever collagen it can make.

Terrain factor	Mechanism
Copper	Essential cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin fibers for tensile strength. Menkes disease — a genetic copper-transport disorder, unrelated to any collagen gene — produces vessel fragility and bleeding tendency through exactly this pathway, showing that disrupted copper availability alone can phenocopy connective-tissue fragility. (StatPearls, NBK560917)
Manganese	Activates prolidase, the enzyme that recycles proline for collagen synthesis. Prolidase deficiency, a separate rare genetic disorder of this pathway, causes poor wound healing — the same precedent logic as copper/Menkes. (Frontiers in Molecular Biosciences, 2021)
Oxidative stress	Reactive oxygen species damage collagen and can cause abnormal, faulty cross-linking — well established in skin-ageing research, biochemically generalisable to other connective tissue. Collagen that's already genetically weaker would plausibly absorb proportionally more damage from the same oxidative load.
GI dysfunction (the strongest EDS-specific link)	With ~90% of hEDS patients reporting gastrointestinal dysfunction, malabsorption becomes a real secondary bottleneck: even adequate dietary intake of copper, manganese, or vitamin C may not be properly absorbed. Unlike the mineral-cofactor mechanisms above, this one is documented directly in hEDS patients, not extrapolated from an analogous condition. (Harris et al., Practical Gastroenterology, 2024)

None of this has been studied as a combination specifically in EDS patients. Each piece stands on real biochemistry or a real analogous disease; none of it is a cure for a genetic condition. It's a case for reducing the cumulative burden on top of the baseline, not for reversing the baseline itself.

The Botanical Protocol

Vitamin C is the one nutrient every collagen-support conversation gets right: it's a genuine, established enzymatic cofactor for the hydroxylation reactions that stabilize the collagen triple helix. Beyond that baseline, a few botanicals stand out on mechanism and evidence quality — graded honestly, not oversold.

Connective Tissue & Circulatory Terrain Protocol

Gotu Kola (Centella asiatica) — the strongest evidence here. Asiaticoside and madecassoside stimulate collagen and glycosaminoglycan synthesis; a meta-analysis of 8 RCTs shows real improvement in chronic venous insufficiency. That evidence comes from vein-wall studies, not EDS itself — a reasonable extrapolation, not a direct finding.
Cissus quadrangularis — traditional Ayurvedic and West African bone-setting plant, active compounds called ketosterones. Real human trial data exists (fracture-healing speed, bone markers), but the summarizing meta-analysis itself grades the evidence quality as low. Worth knowing about, not worth overclaiming.
Vitamin C-dense whole foods — camu camu, acerola, amla (Indian gooseberry) — feed the cofactor collagen synthesis actually requires, rather than isolating it.
Horsetail (Equisetum arvense) — traditional connective-tissue tonic, high silica content, an emerging preclinical (not yet robust human-trial) mechanism for osteoblast collagen production.
Knotgrass (Polygonum aviculare) — traditional pairing with Horsetail. Its flavonoid quercetin-3-O-glucuronide has a real, measured mechanism for strengthening capillary walls and reducing microvascular fragility — a vessel-strengthening effect, not a vasodilating one, which makes it a more POTS-appropriate way to support circulation than the vasodilators flagged earlier. The broader "strengthens connective tissue" claim beyond the vessel wall remains traditional use, not directly tested.
Boswellia serrata — real RCT evidence for joint pain and stiffness via anti-inflammatory action. This addresses joint pain specifically, not the structural laxity itself — relevant if pain is part of your picture, not a fix for connective tissue quality.

Protocol alignment: VORTEX (Cardiovascular Terrain) for the circulatory/POTS layer — deliberately vasoconstriction- and blood-volume-aware rather than vasodilation-first. SGP (Gut Architecture) for the GI-dysfunction bottleneck that limits absorption of everything above. MG (Marine Gnosis) for trace-mineral terrain, including copper and manganese. FRAME (Skeletal Hardware Upgrade) for the broader bone/tendon matrix.

The Point of All This

None of this reverses a genetic mutation. What it does is separate three things that get collapsed into one: the muscle-compensation story that's true but incomplete, the circulatory/autonomic mechanism that explains fatigue sleep can't touch, and the terrain factors — minerals, oxidative load, gut absorption — that plausibly determine how heavy the burden gets on top of the baseline. If a symptom has been dismissed as "just" fatigue for years, the mechanism underneath it usually isn't simple, and it's rarely just muscular.

Sources

Ehlers-Danlos Society. "Prevalence." ehlers-danlos.com/prevalence, 2026.
Hakim A et al. "Chronic fatigue in Ehlers-Danlos syndrome-hypermobile type." American Journal of Medical Genetics Part C, 2017. PMID 28186393
Systematic review, POTS-hEDS comorbidity. ScienceDirect. S1566070219303029
Mathias CJ et al. "Dysautonomia in the Ehlers-Danlos syndromes and hypermobility spectrum disorders." 2021 review.
Harris C et al. Gastrointestinal dysfunction in hEDS. Practical Gastroenterology, 2024.
Systematic review, POTS pharmacotherapy and vasodilator caution. PMC10259876
Systematic review, MCAS comorbidity in hEDS. PMC12063504
Chong PW, Aziz Z. "Systematic review on the chronic venous insufficiency effects of Centella asiatica." Evidence-Based Complementary and Alternative Medicine, 2013. PMC3594936
Meta-analysis, Cissus quadrangularis and bone markers (GRADE: very low certainty). PMC12288206
StatPearls. "Menkes Disease." NBK560917
Frontiers in Molecular Biosciences. Prolidase deficiency review, 2021.
Hippocrates. On the Articulations, Part 8, trans. Francis Adams, 1849. Internet Classics Archive, classics.mit.edu/Hippocrates/artic.8.8.html; parallel Greek/English text, Perseus Digital Library, perseus.tufts.edu (doc=Hp.+Art.)
Hippocrates. Airs, Waters, Places. Hippocratic Corpus.

Read the full terrain framework behind protocols like this one:

The Terrain Architecture →

EDS Fatigue Isn't Muscular.It's Circulatory.